Continuous infusion of piperacillin/tazobactam in ventilator-associated pneumonia: A pilot study on efficacy and costs

International Journal of Antimicrobial Agents

Volumn 39, Issue 2, 2012, Pages 153-158

  Duszynska, Wieslawa ^a   Taccone, Fabio Silvio ^b   Switala, Marcin ^c   Hurkacz, Magdalena ^a   Kowalska Krochmal, Beata ^a   Kübler, Andrzej ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b ERASME HOSPITAL   (Belgium)

^c WROC AW UNIVERSITY OF ENVIRONMENTAL AND LIFE SCIENCES   (Poland)

Author keywords

Lactams; Pharmacoeconomics; Pharmacokinetics; Piperacillin; Ventilator associated pneumonia

Indexed keywords

ANTIBIOTIC AGENT; COTRIMOXAZOLE; NETILMICIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; COST CONTROL; DRUG COST; DRUG EFFICACY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; VENTILATOR ASSOCIATED PNEUMONIA;

AGED; AGED, 80 AND OVER; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; HEALTH CARE COSTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLANIC ACID; PILOT PROJECTS; PIPERACILLIN; PLASMA; PNEUMONIA, VENTILATOR-ASSOCIATED; TREATMENT OUTCOME;

EID: 84855506610     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.10.011     Document Type: Article

References (31)

1. Niederman MS, Craven DE, Bonten MJ, Chastre J, Craig WA, Fagon J, et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. American Thoracic Society; Infectious Diseases Society of America. Am J Respir Crit Care Med 2005;171:388-416.
2. Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005;33:2184-93.
3. Bouza E, Burillo A. Advances in the prevention and management of ventilatorassociated pneumonia. Curr Opin Infect Dis 2009;22:345-51.
4. Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration? Crit Care Med 2009;37:926-33.
5. Taccone FS, Laterre P-F, Dugernier T, Spapen H, Dellatre I, Wittebole X, et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010;14:R126.
6. Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010;35:156-63.
7. Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J. Continuous infusion of β-lactam antibiotics in severe infections: a review of its role. Int J Antimcrob Agents 2007;30:11-8. (Pubitemid 46874893)
8. McKinon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008;31:345-51.
9. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 2005;56:388-95. (Pubitemid 41158530)
10. Lorente L, Jiménez A, Martín MM, Iribarren JL, Jiménez JJ, Mora ML. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009;33:464-8.
11. Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents 2005;25:62-7. (Pubitemid 40023348)
12. Rafati MR, Rouni MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K, et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006;28:122-7. (Pubitemid 44108605)
13. Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. Piperacillin-tazobactam: a β-lactam/β-lactamase inhibitor combination. Expert Rev Anti Infect Ther 2007;5:365-83.
14. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6. (Pubitemid 36444440)
15. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-32 [Erratum in: Am J Infect Control 2008;36:655]. (Pubitemid 351763841)
16. Rosbolt MB, Sterling ES, Fahy BG. The utility of the clinical pulmonary infection score. J Intensive Care Med 2009;24:26-34.
17. Baughman RP. Microbiologic diagnosis of ventilator-associated pneumonia. Clin Chest Med 2005;26:81-6. (Pubitemid 40410706)
18. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI; 2010.
19. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
20. ICH harmonised tripartite guideline. Validation of analytical procedures: text and methodology. Q2(R1). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2005. http://www.ich.org/fileadmin/Public Web Site/ICH Products/Guidelines/ Quality/Q2 R1/Step4/Q2 R1 Guideline.pdf [accessed July 2011].
21. Kuti JL, Nightingale CH, Quintiliani R, Nicolau DP. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn Microbiol Infect Dis 2002;44:51-7.
22. Tam VH, Gamez EA, Weston JS, Gerard LN, Larocco MT, Caeiro JP, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008;46:862-7. (Pubitemid 351417187)
23. Lau WK, Mercer D, Itani KM, Nicolau DP, Kuti JL, Mansfield D, et al. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006;50:3556-61. (Pubitemid 44684865)
24. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002;22:471-83. (Pubitemid 34270031)
25. Lodise Jr TP, Lomaestro BM, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007;44:357-63. (Pubitemid 46147617)
26. Strayer AH, Gilbert GH, Pivarnik P, Medeiros AA, Zinner SH, Dudley MN. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Antimicrob Agents Chemother 1994;38:2351-6. (Pubitemid 24304229)
27. Williamson R, Tomasz A. Inhibition of cell wall synthesis and acylation of the penicillin binding proteins during prolonged exposure of growing Streptococcus pneumonia to benzylpenicillin. Eur J Biochem 1985;151:475-83. (Pubitemid 16215779)
28. Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991;27(Suppl. C):29-40.
29. Udy AA, Roberts JA, Boots RJ, Patterson DL, Lipman J. Augmented renal clearance: implications for antimicrobial dosing in the critically ill. Clin Pharmacokinet 2010;49:1-16.
30. Baptista JP, Udy AA, Sousa E, Pimental J, Wang L, Roberts JA, et al. A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care 2011;15:R139.
31. Boselli E, Breilh D, Rimelle T, Guillaume C, Xuerelo F, Saux M-C, et al. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med 2008;36:1500-6. (Pubitemid 351620671)